Analysts Set Target Price of $19.67 for Cogent Biosciences Stock

Shares of Cogent Biosciences, Inc. (NASDAQ: COGT) have received an average recommendation of “Moderate Buy” from fourteen brokerages currently covering the firm, according to MarketBeat. The consensus target price among these analysts stands at $19.67, reflecting a diverse range of opinions on the stock’s future performance.

A deeper look into the analysts’ ratings reveals mixed sentiments. One research analyst has issued a sell recommendation, four analysts suggest a hold, seven recommend buying, and two have provided strong buy ratings. Analysts have actively adjusted their price targets for Cogent Biosciences in recent weeks, showcasing the evolving market outlook.

Recent Analyst Activity

On August 6, HC Wainwright revised its price target for Cogent Biosciences from $22.00 to $21.00, maintaining a “buy” rating. The following day, JPMorgan Chase & Co. increased its target from $29.00 to $30.00 while assigning an “overweight” rating. Notably, Robert W. Baird lifted its target from $7.00 to $9.00, giving the stock a “neutral” rating on July 8. Similarly, Leerink Partners raised its target from $16.00 to $18.00, labeling it as “outperform.” Conversely, Weiss Ratings reiterated a “sell (e+)” rating in a report dated October 8.

Cogent Biosciences Stock Performance

As of Thursday, shares of Cogent Biosciences opened at $16.22. The stock has demonstrated significant volatility over the past year, with a low of $3.72 and a high of $17.00. Currently, the company’s market capitalization is approximately $1.85 billion. The stock’s price-to-earnings (P/E) ratio stands at -9.11, with a beta of 0.30, indicating lower volatility compared to the market.

In the most recent quarterly earnings report released on August 5, Cogent Biosciences reported earnings per share (EPS) of ($0.53), surpassing analysts’ expectations of ($0.55) by $0.02. Analysts forecast that the company will post an EPS of ($2.42) for the current year.

Cogent Biosciences focuses on developing precision therapies for genetically defined diseases. Its lead product candidate is bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor targeting mutations within the KIT receptor tyrosine kinase. This includes the KIT D816V mutation, a significant factor in systemic mastocytosis, as well as other mutations in KIT exon 17, which are prevalent in patients with advanced gastrointestinal stromal tumors.

As the market continues to react to these developments, investors and analysts alike remain attentive to the stock’s performance and the company’s strategic direction.